

Supplement

SPLUNC1: A Novel Marker of Cystic Fibrosis Exacerbations

Sara Khanal, Megan Webster, Naiqian Niu, Myra Nunez, Geoffrey Chupp, Martin D. Slade, Lauren Cohn, Maor Sauler, Jose L. Gomez, Robert Tarran, Lokesh Sharma, Charles S. Dela Cruz, Marie Egan, Theresa Laguna, Clemente J. Britto

Detailed Methods

Study Design

This was a two-center, prospective, longitudinal cohort study of CF subjects during periods of clinical stability and AE. All patients received standard-of-care therapies as recommended by CF Foundation guidelines, including airway clearance, nutritional support, antibiotics when indicated, and cystic fibrosis transmembrane conductance regulator (CFTR) modulators when they became clinically available. Each subject provided a sputum sample and underwent spirometry within 24 hours of sample collection. Subjects were followed at quarterly outpatient clinic visits, or sooner when indicated, for up to one year (Supplemental figure 1). Clinical information, expectorated sputum samples and pulmonary function testing data were collected at each clinic visit. Sputum was processed as previously described and frozen immediately after collection [1]. The primary objective of this study was to define an association between AE and sputum levels of SPLUNC1.

Definition of CF Exacerbation

A CF exacerbation was defined as the emergence of 4 of 12 signs or respiratory symptoms, prompting a change in therapy and initiation of antimicrobial treatment (modified from Fuchs' criteria [2]). These criteria included: change in sputum; change in hemoptysis; increased cough; increased dyspnea; malaise, fatigue or lethargy; fever; hyporexia or weight loss; sinus congestion; change in sinus discharge; change in chest physical exam; or FEV₁ decrease >10% from a previous value [2]. Individuals without new symptoms and those that did not meet AE criteria were characterized as "CF Stable".

Subject Cohorts

Yale Cohort (Discovery cohort): Forty-four adult subjects with a confirmed diagnosis of CF from the Yale Adult CF Program participated in this study. These subjects were recruited during a) scheduled routine visits, b) unscheduled "sick" visits, in which they reported AE symptoms, and c) on the first day of admission to the hospital for AE treatment. Our recruitment period extended from 2014-2016. We organized study subjects in two groups: 1) Stable CF subjects (CF Stable): No new respiratory symptoms, presenting to clinic for scheduled quarterly follow up and, 2) AE subjects (AE): Those diagnosed with AE that were prescribed treatment with a change in airway clearance and antibiotics (*Table 1*).

We also recruited ten healthy volunteers (Healthy Controls, HC) to undergo sputum induction according to previous protocols [3]. The study protocol was approved by the Yale University Institutional Review Board and informed consent was obtained from each subject.

University of Minnesota (UMN, Validation cohort): Thirty-five adult and pediatric subjects with a confirmed diagnosis of CF, previously enrolled in a sputum study of AE at UMN were included as a validation cohort. This was a prospective cohort study of patients hospitalized for AE treatment [4]. All patients received standard-of-care therapies. Each subject performed pulmonary function tests (PFT) within 72 hours of the initiation of intravenous antibiotics and provided sputum samples (*Table 2*)[5].

Sputum Collection and Processing

CF subjects with or without AE expectorated sputum spontaneously for routine airway cultures and provided an additional sample for our studies. Induced sputum samples were obtained from HC as previously described [3, 6]. Briefly, subjects inhaled nebulized 3% hypertonic saline for 5 minutes on three cycles. To reduce squamous cell contamination, subjects were asked to rinse their mouth with water and clear their throat. Expectorated sputum samples were collected into specimen cups and placed on ice. Sputum plug material from HC and CF subjects were

selected and weighed prior to washing with 9x their volume of PBS. Samples were incubated in Dulbecco's Phosphate-Buffered Saline (DPBS) with agitation for 15 minutes and centrifugated. Supernatants were stored at -80°C.

SPLUNC1 and Cytokine ELISA, Western Blot

Sputum SPLUNC1 concentration was measured in supernatants using a direct human SPLUNC1 ELISA. Human SPLUNC1 recombinant protein was used as standard reference (cat# H00051297-P01, Abnova, Taipei, Taiwan). Detection antibody: polyclonal mouse anti-human SPLUNC1 IgG (1:000, cat# SAB1401687, MilliporeSigma, Burlington, MA). This antibody recognizes the following amino acid sequence within the SPLUNC1 protein: MFQTGGLIVFYGLLAQTMAQFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALSNGLLSGGLLGILENLP LLDILKPGGGTSGLLGGLLGKVTSVIPGLNIIIDIKVTDPQLLELGLVQSPDGHRLVYTIPLGIKLVQNTPLV GASLLRLAVKLDITAEILAVRDKQERIHVLGDC THSPGSLQISLLDGLGPLPIQGLLDSL TGILNKVLP ELVQ GNVCP LVNEVLRGLDITLVH DIVNMLIHGLQFVIKV. Secondary antibody: anti-mouse IgG HRP-conjugated (1:2500, cat# G21040, Invitrogen, Carlsbad, CA). 3,3',5,5'-tetramethylbenzidine substrate was applied (KPL, Gaithersburg, MD). Reactions were measured at optical densities of 450 and 550 nm. The limits of detection of this assay ranged 1 ng/mL - 20,000 ng/mL. The SPLUNC1 intra- and inter-assay variability was calculated using 5 randomly selected HC and 8 CF sputum samples. For inter-assay variability, SPLUNC1 was measured in duplicate in two separate plates on days. Mean intra-assay variability was calculated at 5.18% (STDEV 1.28%) and inter-assay variability at 18.44% (STDEV 12.95%). Specimens were run in duplicate, using four serial dilutions to ensure reproducibility. For sputum cytokine detection we used custom-made multiplexed cytokine ELISA assays (Mesoscale Diagnostics, Rockville, MD, coefficient of variability <25%).

For Western blots, supernatant total protein concentrations were determined by BCA assay (Thermo Fisher Scientific, Waltham, MA) and 20 µg of total protein was loaded for each sample onto 4-15% Bis-Tris gels (BioRad, Hercules, CA). Samples were electrophoresed at 130 volts. Gels were transferred onto PDVF membranes and probed for human neutrophil elastase (NE, hELA2) using mouse monoclonal anti-hELA2 (1:3000, cat# MAB-91671-100, R&D systems), membranes were then stripped and re-probed using SPLUNC1 antibody (The same SPLUNC1 antibody as ELISA). Membranes were developed using chemiluminescence. Densitometry determined using ImageJ software.

Sputum Neutrophil Elastase Quantification and Activity

NE activity was determined using the elastase specific substrate Suc-Ala-Ala-Ala-MCA (#MAA-3133; Peptides International, Louisville, KY) at a final concentration of 100 µM, as described previously [7]. The fluorogenic substrate is cleaved to generate the reaction product 7-amino-4-methylcoumarin (AMC), whose fluorescence is measured by spectrophotometry. Briefly, sputum was diluted 1:1 with assay buffer (115 mM NaCl; 10 mM HEPES). 10 µl of sputum-buffer mix was added per well, and 10 µl of 100 µM MAA-3133 added to each well. Assays were performed at 37°C in a Tecan infinite M1000 plate-reader, with fluorescence readings taken every 15 minutes. Samples were excited at 380 ± 5 nm and emitted fluorescence collected at 460 ± 10 nm. Resultant AMC concentrations were determined from a standard curve with linear regression.

Measurements of SPLUNC1 Degradation by Human and Bacterial Elastase

Recombinant human SPLUNC1 was incubated with recombinant human neutrophil elastase (rhNE, R&D systems cat#9167-SE-020) or *Pseudomonas aeruginosa* elastase (LasB, a gift from Dr. Karen Agaronyan, Yale) diluted to a final concentration of 5 µg/ml for 24 hours. SPLUNC1 ELISA was performed at the end of the assay.

Regulation of Epithelial Expression by Cytokines

Mouse tracheal epithelial cells (mTECs) were isolated from C57BL/6 mice and cultured on transwell plates at air-liquid interface (ALI) as previously described [8]. mTECs were treated with recombinant murine IL-1β (cat# 211-11b, Peprotech, Rocky Hill, NJ) or TNF-α (cat# 315-01A, Peprotech, Rocky Hill, NJ), at 10 for 24 hours. NCI-H292 human airway epithelial cells (shown to express high levels of SPLUNC1 and to be robustly regulated by inflammatory cytokines[8]), were cultured to confluence and treated with recombinant human IL-1β (cat# PHC0811, Gibco, Gaithersburg, MD) or TNF-α (cat# 210-TA-005, R&D, Minneapolis, MN) at 10 ng/ml. Cellular mRNA was extracted from individual wells for qPCR using RNeasy plus lysis buffer (cat# 74134, Qiagen, Hilden, Germany). After measuring the RNA levels of the samples, 1 µg of RNA was used to synthesize cDNA using the iScript reaction mix (cat# 170-8891, Biorad, Hercules, CA). After cDNA synthesis, SYBR Fast qPCR Kit (cat#

kk4619, MilliporeSigma, Burlington, MA) was used to run the qPCR assay. Murine PCR primers used for amplification included SPLUNC1 (5'-GTCCACCCCTGCCACTGAACCA-3' and 3'-CACCGCTGAGAGCATCTGTGAA-5') and β -actin (5'-GTCCACACCCGCCACCAGTTCG and 3'-GACCCATTCCCACCATCACACCCT-5'). Human PCR primers used for amplification included SPLUNC1 (5'-TGCTGGAACCTGGCCTTGTGCA-3' and 3'-ACCAGGGGCGTATTCACCTGGA-5') and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 5'-TGGAGAAGGCTGGGGGCTCATTT-3' and 3'-TGGTGCAGGAGGCATTGCTGAT-5'). For each set of primers, validation experiments showed a linear dependency of threshold cycle values at different RNA concentrations. The data were analyzed after murine genes were normalized to β -actin and human genes were normalized to GAPDH. To run the qPCR, 384-well reaction plate with master mix, sample, and primers was prepared (cat# 4309849, Applied Biosystems, Foster City, CA) and the assay was run in the Vii7 Real Time PCR System (Applied Biosystems, Foster City, CA). Both experiments were performed twice.

Statistical Analysis

Descriptive statistics were calculated for the entire subject population. Pearson correlations, or Spearman correlations for variables that were not normally distributed, were calculated between SPLUNC1 and clinical parameters. In order to select the optimal threshold of SPLUNC1 and cytokine concentrations that identify a subject group at higher AE risk, we calculated receiver-operating curves (ROC) based on the distribution of SPLUNC1, IL-1 β , TNF α , G-CSF, IL-6, and IL-8 levels in the discovery cohort (Supplemental Figure 3). Using this threshold, we applied statistical modeling (Mantel-Haenszel estimator) to predict AE-free intervals. AE interval was defined as the time in days from sputum sampling in a stable subject to the time of the first AE after that visit. Cox proportional hazards model was conducted with clinical parameters as covariates. A backward elimination strategy with a significance level to stay of 95% ($\alpha=0.05$) was employed to achieve a parsimonious model. Note that the predictor of interest was forced to be included in the parsimonious model. All statistical analyses were conducted using SAS 9.4 with a level of significance of 95% ($\alpha=0.05$).

REFERENCE

1. Yao Y, Welp T, Liu Q, Niu N, Wang X, Britto CJ, Krishnaswamy S, Chupp GL, Montgomery RR. Multiparameter Single Cell Profiling of Airway Inflammatory Cells. *Cytometry B Clin Cytom* 2017; 92(1): 12-20.
2. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. *The New England journal of medicine* 1994; 331(10): 637-642.
3. Yan X, Chu JH, Gomez J, Koenigs M, Holm C, He X, Perez MF, Zhao H, Mane S, Martinez FD, Ober C, Nicolae DL, Barnes KC, London SJ, Gilliland F, Weiss ST, Raby BA, Cohn L, Chupp GL. Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma. *American journal of respiratory and critical care medicine* 2015; 191(10): 1116-1125.
4. Laguna TA, Williams CB, Brandy KR, Welchlin-Bradford C, Moen CE, Reilly CS, Wendt CH. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis. *Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society* 2015; 14(3): 334-340.
5. Laguna TA, Wagner BD, Luckey HK, Mann SA, Sagel SD, Regelman W, Accurso FJ. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis. *Chest* 2009; 136(6): 1561-1568.
6. Esther CR, Jr., Peden Db Fau - Alexis NE, Alexis Ne Fau - Hernandez ML, Hernandez ML. Airway purinergic responses in healthy, atopic nonasthmatic, and atopic asthmatic subjects exposed to ozone. 2011(1091-7691 (Electronic)).
7. Webster MJ, Reidel B, Tan CD, Ghosh A, Alexis NE, Donaldson SH, Kesimer M, Ribeiro CMP, Tarran R. SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration. *Eur Respir J* 2018; 52(4).
8. Britto CJ, Liu Q, Curran DR, Patham B, Dela Cruz CS, Cohn L. Short palate, lung, and nasal epithelial clone-1 is a tightly regulated airway sensor in innate and adaptive immunity. *American journal of respiratory cell and molecular biology* 2013; 48(6): 717-724.